Bo Carlsson
Karo Pharma (Sweden) · 15 works · 9,745 citations · h-index 10
Top works
- Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β
- Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β
- Differential Response of Estrogen Receptor α and Estrogen Receptor β to Partial Estrogen Agonists/Antagonists
- Expression of a novel member of estrogen response element-binding nuclear receptors is restricted to the early stages of chorion formation during mouse embryogenesis
- High level expression of functional full length human thyroid hormone receptor β1 in insect cells using a recombinant baculovirus
- Characterization of bacterially expressed rat estrogen receptor β ligand binding domain by mass spectrometry: Structural comparison with estrogen receptor α
- Quantitative Determination of DNA-Binding Parameters for the Human Estrogen Receptor in a Solid-Phase, Nonseparation Assay
- Thyroid Receptor Ligands. 6. A High Affinity “Direct Antagonist” Selective for the Thyroid Hormone Receptor
- Discovery of 3-Cyano- N -(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H -pyrrolo[2,3- b ]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist
- Thyroid Receptor Ligands. 3. Design and Synthesis of 3,5-Dihalo-4-alkoxyphenylalkanoic Acids as Indirect Antagonists of the Thyroid Hormone Receptor
- Inefficacy of topical thyroid hormone analogue TriAc in plaque psoriasis: results of a double-blind placebo-controlled trial
- Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity
- Application of a Novel Method for the Comparison of DNA Binding Parameters of the Two Human Thyroid Hormone Receptor Subtypes hTRα1and hTRβ1
- Scintillating microtitration plates in model experiments measuring hormone and DNA binding to the human thyroid hormone receptor
- Abstract: 1463 EPROTIROME: A PHYSIOLOGICAL APPROACH TO LIPID CONTROL UTILIZING A LIVER SELECTIVE THYROID HORMONE RECEPTOR AGONIST